Versluis et al. examine disease recurrence after initial pathologic response to neoadjuvant immune checkpoint inhibition in stage III melanoma. As no genetic changes in the tumor cells mediating immune evasion are found, it is proposed that disease recurrence may potentially be explained by diminishing of the initial therapy-induced immune response.
- Judith M. Versluis
- Huma Shehwana
- Christian U. Blank
